ELV

In the past six months, Elevance Health's stock has been influenced by several key events. In the fourth quarter of 2025, the company reported operating revenue of $49.3 billion, an increase of 10% compared to the prior year quarter. Entering 2026, Elevance Health delivered first-quarter results ahead of expectations, with operating revenue of $49.5 billion, up 1.5% from Q1 2025. The company subsequently raised its full-year 2026 adjusted EPS guidance to at least $26.75. An unresolved government investigation into Medicare Advantage risk-adjustment coding irregularities has been a key investor concern. Analyst ratings have varied, with some downgrades in price targets despite overall positive sentiment from strong Q1 results.